Plant Name: Citrus reticulata
Taxonomic Information:
Plant ID: NPO25443
Plant Latin Name: Citrus reticulata
Taxonomy Genus: Citrus
Taxonomy Family: Rutaceae
Plant External Links:
NCBI TaxonomyDB:
85571
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Thailand; Argentina; China; India; South KoreaTraditional Medicine System:
Sowa-Rigpa; TCM; Unani; AyurvedaMedicinal Functions:
Analgesic; Antiasthmatic; Anticholesterolemic; Antiemetic; Antiinflammatory; Antiscorbutic; Antiseptic; Antitussive; Aphrodisiac; Astringent; Carminative; Expectorant; Laxative; Miscellany; Stomachic; Tonic
Geographical Distribution:
India; Argentina; China; South Korea; Thailand
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| FFAR1; FFAR4; TAAR1; | |
| ACHE; | |
| FAAH; BLM; HSD17B10; ALOX15; ALDH1A1; | |
| HTR3A; | |
| TRPV1; | |
| PIM1; | |
| CA2; CA12; CA9; CA14; CA7; CA4; | |
| PPARA; | |
| THRB; | |
| RXRA; | |
| KDM4E; | |
| MMP9; MMP1; MMP2; | |
| TP53; HIF1A; NFKB1; | |
| FUT7; | |
| ABCB1; | |
| SLCO1B1; | |
| LMNA; FABP3; FABP5; FABP4; MCL1; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| 5HT3 receptor | HTR3A | Serotonin 3a (5-HT3a) receptor | P46098 | CHEMBL1899 |
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 2 group B | RXRA | Retinoid X receptor alpha | P19793 | CHEMBL2061 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | TAAR1 | Trace amine-associated receptor 1 | Q96RJ0 | CHEMBL5857 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.079E-13 | 6.704E-09 | CA12, CA14, CA2, CA4, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.151E-10 | 2.107E-06 | CA12, CA14, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.982E-09 | 1.520E-05 | BLM, CA12, CA2, CA4, CA7, CA9, MMP1, MMP2, MMP9, PPARA, RXRA, THRB, TP53 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.202E-08 | 2.181E-05 | CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 2.959E-07 | 3.221E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 9.439E-07 | 9.787E-04 | ACHE, ALDH1A1, CYP19A1, CYP1B1, FFAR1, FFAR4, HIF1A, NFKB1, SLCO1B1 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 1.054E-06 | 1.043E-03 | ABCB1, CA2, CA7 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.898E-06 | 2.337E-03 | HIF1A, MMP1, MMP2, MMP9, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:1901652; response to peptide | 7.844E-06 | 4.880E-03 | FABP3, FFAR4, NFKB1, PPARA, TP53, TRPV1, TSHR |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.317E-05 | 6.994E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0009056; catabolic process | 1.401E-05 | 7.091E-03 | ACHE, ALDH1A1, CYP19A1, CYP1B1, FAAH, FABP3, FABP4, FABP5, FUT7, HSD17B10, MMP1, MMP2, MMP9, TP53 |
| BP | GO:0009987; cellular process | GO:0051289; protein homotetramerization | 1.805E-05 | 8.735E-03 | HSD17B10, RXRA, TP53, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 1.908E-05 | 9.033E-03 | ABCB1, BLM, CA9, CYP1B1, FABP3, HTR3A, NFKB1, TP53, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.976E-05 | 9.156E-03 | FABP3, FABP4, FABP5 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 6.162E-13 | 7.087E-11 | CA12, CA2, CA4, CA7, CA9, CA14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 5.521E-09 | 3.174E-07 | FABP3, RXRA, FABP4, FABP5, MMP1, PPARA |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.457E-06 | 5.584E-05 | MMP1, MMP2, MMP9, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 2.164E-06 | 6.223E-05 | ABCB1, PIM1, CYP1B1, TP53, MMP9, NFKB1, MCL1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.447E-05 | 2.772E-04 | RXRA, MMP1, MMP2, HIF1A, TP53, MMP9, NFKB1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.337E-05 | 2.772E-04 | SLCO1B1, ABCB1, RXRA, CA2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 9.851E-05 | 1.618E-03 | RXRA, THRB, TP53, HIF1A |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.905E-04 | 2.434E-03 | LMNA, TP53, NFKB1, MCL1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.564E-04 | 2.248E-03 | RXRA, PPARA, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 7.777E-04 | 6.880E-03 | MMP2, TP53, HIF1A, MMP9 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 3.979E-04 | 4.576E-03 | RXRA, PPARA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 4.954E-04 | 5.180E-03 | RXRA, TP53, MMP9, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.159E-03 | 8.887E-03 | MMP2, PIM1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 7.272E-04 | 6.880E-03 | RXRA, TP53, NFKB1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.009E-03 | 8.292E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | HTR3A; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; ABCB1; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | FAAH; ACHE; TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | TRPV1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; TP53; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | THRB; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1; |
| C00-D49: Neoplasms | Cutaneous T-cell lymphoma | C84.0, C84.1 | RXRA; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; NFKB1; ACHE; HIF1A; MMP9; TP53; MMP2; MCL1; ABCB1; CA9; |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | HTR3A; TRPV1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TRPV1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; MMP9; TP53; MMP2; ABCB1; CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| NA: NA | Vomiting | NA | HTR3A; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | FAAH; ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR3A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Local anaesthetic | R20.0 | HTR3A; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR3A; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| NA: NA | Esophagus sensitivity | NA | TRPV1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR3A; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
